transforming-growth-factor-beta and 5-7-dihydroxy-6-methoxy-2-phenylchromen-4-one

Topics: Anti-Inflammatory Agents; beta Catenin; Caspases; Chronic Disease; Flavonoids; Humans; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A

Oroxylin A (OA), a naturally occurring monoflavonoid isolated from Scutellariae radix, has previously been reported to inhibit the proliferation of several cancer cell lines. CD4+CD25+Foxp3+ regulatory T cells (Tregs) play an important role in maintenance of immunologic self-tolerance. Tregs also increase in cancer and take part in suppressing antitumor immune responses. Here, we explored how OA affected the Tregs in lung cancer environment and the involved underlying mechanism. It is found that OA reversed the generation of Tregs induced by H460 lung cancer cells co-culture. Furthermore, in vivo, OA reduced tumor formation rate and attenuated Foxp3 expression in tumor-infiltrating lymphocytes. We also found that transforming growth factor-β1 (TGF-β1) neutralizing antibody reversed the enhancement of Treg number and expression of p-Smad3'p-p38'p-JNK'p-ERK1/2 in the co-culture model. Moreover, OA reduced the secretion of TGF-β1 and down-regulated the activation of NF-κB signaling in H460 cells. OA also inhibited Treg activity by a direct inhibition of the T cells' response to TGF-β1. In conclusion, our study demonstrated that OA inhibits the generation of Tregs in lung cancer environment by inhibiting the T cells' response to TGF-β1 and decreasing the secretion of TGF-β1 in lung cancer cells via NF-κB signaling.

Topics: Animals; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Coculture Techniques; Disease Models, Animal; Flavonoids; Humans; Immunophenotyping; Jurkat Cells; Leukocytes, Mononuclear; Lung Neoplasms; Mice; NF-kappa B; Signal Transduction; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Xenograft Model Antitumor Assays